Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Epcoritamab monotherapy demonstrates promising efficacy in patients with Richter transformation (RT): 2-year follow-up results from arm 2A of the phase 1b/2 EPCORE CLL-1 trial

View Full Paper
Ask AI
Bookmark
Share

Authors

AKArnon P. KaterDutch Cancer SocietyJSJose Sandoval‐SusMoffitt Cancer CenterMSMazyar ShadmanUniversity of Washington

Discussion

Loading...

Member takes

Implication

Epcoritamab demonstrates improved survival and response rates in Richter transformation, suggesting potential as a standard care option.

Key Points

  • To evaluate the efficacy and safety of epcoritamab monotherapy in patients with Richter transformation.
  • Patients with CD20+ DLBCL and history of CLL received epcoritamab 48 mg in cycles until disease progression.
  • Follow-up included assessment of overall response rate, complete response rate, progression-free survival, and overall survival.
  • Corticosteroid prophylaxis was utilized to mitigate cytokine release syndrome.
  • Overall response rate was 48% and complete response rate was 40% in the total study population.
  • In first-line therapy, overall response rate was 57%, with 52% achieving complete response.
  • Median overall survival exceeded 2 years in patients receiving epcoritamab as first-line therapy.

Cite This Study

Kater et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d419https://doi.org/10.1182/blood-2025-1017
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Epcoritamab combinations demonstrate promising efficacy in patients (pts) with Richter transformation (RT): First results from arms 2B (epcor + lenalidomide [LEN]) and 2C (epcor + R-CHOP) of the phase 1b/2 EPCORE CLL-1 trial2025
  2. 2Sustained remissions beyond 4 years with epcoritamab monotherapy: Long term follow-up results from the pivotal EPCORE NHL-1 trial in patients with relapsed or refractory large B-cell lymphoma2025
  3. 3Fixed-duration epcoritamab monotherapy induces high response and MRD-negativity rates in elderly patients with newly diagnosed large B-cell lymphoma (LBCL) and comorbidities: Results from EPCORE DLBCL-32025 · 2 citations
  4. 4Epcoritamab + R-DHAX/C in transplant-eligible patients (pts) with high-risk relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).2024 · 14 citations
  5. 5Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: Subcutaneous epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).2024 · 9 citations